Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | USP5 | P45974 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931479 | 1.00 | USP30 (0.38) | USP30HTR2AHTR2CHTR2BUSP5 | |
| SCHEMBL8451674 | 0.95 | USP5 (0.37) | USP30HTR2AHTR2CHTR2BUSP5 | |
| SCHEMBL2272516 | 0.95 | USP5 (0.37) | USP30HTR2AHTR2CHTR2BUSP5 | |
| SCHEMBL2272518 | 0.95 | USP5 (0.37) | USP30HTR2AHTR2CHTR2BUSP5 | |
| SCHEMBL2272522 | 0.95 | USP5 (0.37) | USP30HTR2AHTR2CHTR2BUSP5 | |
| SCHEMBL9312459 | 0.91 | USP30 (0.39) | USP30HTR2AHTR2CHTR2BUSP5 | |
| SCHEMBL8517432 | 0.91 | USP30 (0.39) | USP30HTR2AHTR2CHTR2BUSP5 | |
| Trifluoroacetic Acid SCHEMBL28713069 | 0.88 | DPP4 (0.38) | USP30USP5HDAC6HCRTR2KDM1A | |
| SCHEMBL8379901 | 0.87 | P2RY14 (0.39) | KDM1AHDAC2 | |
| SCHEMBL8378329 | 0.87 | P2RY14 (0.39) | KDM1AHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080173844-A1 | PHENYLCYCLOHEXANES AND A LIQUID-CRYSTALLINE MEDIUM | WACHTLER ANDREAS | 2008-07-24 | — | — | US | disclosed |
| US-7250199-B2 | Phenylcyclohexanes and a liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2007-07-31 | — | — | US | disclosed |
| US-6955837-B2 | Phenylcyclohexanes and a liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2005-10-18 | — | — | US | disclosed |
| US-20050133763-A1 | Phenylcyclohexanes and a liquid-crystalline medium | WACHTLER ANDREAS (DE) | 2005-06-23 | — | — | US | disclosed |
| US-20040169159-A9 | Phenylcyclohexanes and a liquid-crystalline medium | MERCK KGAA (DE) | 2004-09-02 | — | — | US | disclosed |
| US-20040089845-A1 | Phenylcyclohexanes and a liquid-crystalline medium | WACHTLER ANDREAS (DE) | 2004-05-13 | — | — | US | disclosed |
| US-6677002-B2 | FLUORO, OXYMETHYLDIFLUORO OR OXYMETHYLTRIFLUORO, CHLORO OR CYANO DERIVATIVES OF PHENYLCYCLOHEXANES AS COMPONENTS OF LIQUID CRYSTALLINE MEDIA FOR ELECTROOPTICAL DISPLAYS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20020043646-A1 | Phenylcyclohexanes and a liquid-crystalline medium | MERCK KGAA (DE) | 2002-04-18 | — | — | US | disclosed |
| US-6284154-B1 | FOR LIQUID CRYSTAL CELLS, ELECTROPTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2001-09-04 | — | — | US | disclosed |
| US-20010015422-A1 | Phenylcyclohexanes and a liquid-crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2001-08-23 | — | — | US | disclosed |
| EP-0438574-B1 | 2,5-DISUBSTITUTED HETEROCYCLES AND MESOMORPHOUS MEDIUM | MERCK PATENT GMBH (DE) | 1995-01-25 | — | — | EP | disclosed |
| EP-0438563-B1 | PHENYLCYCLOHEXANES AND LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 1994-12-07 | — | — | EP | disclosed |
| US-5322638-A | Halophenyl substituted dioxanes | HOFFMANN-LA ROCHE INC. (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0422958-B1 | Dicyclohexylethylene derivatives | CHISSO CORP (JP) | 1994-04-27 | — | — | EP | disclosed |
| US-5250220-A | Electro-optical displays | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-10-05 | — | — | US | disclosed |
| US-5055220-A | For liquid crystal displays | CHISSO CORPORATION (JP) | 1991-10-08 | — | — | US | disclosed |
| EP-0433836-A2 | Halophenyl substituted dioxanes | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-26 | — | — | EP | disclosed |
| EP-0422958-A1 | Dicyclohexylethylene derivatives | Chisso Corporation (JP) | 1991-04-17 | — | — | EP | disclosed |
| WO-1991002709-A1 | PHENYLCYCLOHEXANES AND LIQUID CRYSTAL MEDIUM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-03-07 | — | — | WO | disclosed |
| WO-1991002780-A1 | 2,5-DISUBSTITUTED HETEROCYCLES AND MESOMORPHOUS MEDIUM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040089845-A1 | Phenylcyclohexanes and a liquid-crystalline medium | HCFC1, CYP2F1, CCR1 | USP30 4672/4885HTR2A 1623/4885HTR2C 540/4885 |
| US-20080173844-A1 | PHENYLCYCLOHEXANES AND A LIQUID-CRYSTALLINE MEDIUM | CYP2F1, CYP4F3, POF1B | USP30 3808/4885HTR2A 1644/4885HTR2C 593/4885 |
| US-20020043646-A1 | Phenylcyclohexanes and a liquid-crystalline medium | CYP2F1, HCFC1, CYP4F11 | USP30 4763/4885HTR2A 1789/4885HTR2C 609/4885 |
| US-20040169159-A9 | Phenylcyclohexanes and a liquid-crystalline medium | CYP2F1, HCFC1, CYP4F11 | USP30 4763/4885HTR2A 1789/4885HTR2C 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.